Research Library

Despite right-wing pushes for the annexation of a significant portion of the West Bank, support remains for a two-state solution to the ongoing Israeli-Palestinian conflict. Yair Hirschfeld, fellow in the Center for the Middle East, analyzes Israel's political environment in this post on the Baker Institute Blog.

The 340B Drug Pricing Program, which allows uninsured or low-income patients to buy prescription drugs at discounted prices, is under attack.

Baker Institute experts blog on opportunities for the U.S. and Mexico to jointly address the neglected tropical diseases found among the poorest people living in both countries.

In this commentary, the authors examine the roots of the United States’ reluctance to embrace universal health care, concluding that it "is neither sound nor ethical in a nation that promulgates fairness and equal opportunity" to deny coverage.

Asthma in children costs an estimated $27 billion annually for doctor visits, emergency department visits and hospitalizations. Not surprisingly, kids with asthma miss more days of school and do worse academically. The first step to the management and treatment of asthma is access to a primary care provider who can prescribe the necessary medications and develop an asthma action plan. However, if we want to have a significant impact on the negative consequences of this disease on our children, a multi-faceted approach that includes policy is an absolute must.

Genomic testing is a rapidly growing field, especially in cancer medicine, where it can be used to match patients to the most effective targeted treatment. In the past decade, we have seen rapid growth in the number of new genomic tests that are available. However, genomic testing is usually very expensive, raising the question of whether the testing is worth the cost.

Drug policy has experienced an interesting shift recently. Along with legalization of medical and recreational marijuana, many states are also reducing penalties for nonviolent drug offenses and placing greater focus on treatment for drug users. The emphasis on treatment and rehabilitation for drug users is the result of many factors, including recognition that the drug war has not reduced drug use, a desire to reduce the prison population and save money, and a surge in the rate of overdoses from opioid and heroin use. What remains to be seen is whether the current popularity of drug treatment will become a more permanent feature of drug policy. In this Baker Institute Viewpoints series, five experts on drug policy examine the question, “Is the current emphasis on treatment in drug policy a short-term trend or is it here to stay?”